Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

NCT03361358 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2020-03-16

No results posted yet for this study

Summary

The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.

Conditions

Sponsors & Collaborators

  • Agios Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03361358 on ClinicalTrials.gov